stockrow
Saturday 7 November 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
- Revenue
- −5.30%
- EPS
- +102.0%
- Free cash flow
- −10.9%
- Total debt
- −1.51%
Quarter to June 2026, against a year earlier
0.76
0.03
+4.11%
Follow CELU
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 14 | 21 | 18 | 23 | 54 | 27 | 19 | +13.2% | — | — | — | — | |
| Gross margin, % | — | — | — | — | 65.46 | 54.76 | (9.40) | 29.66 | 72.36 | 24.39 | 19.23 | (41.1) pt | ||||||
| EBT | — | — | 0 | 7 | (213) | (100) | 14 | (196) | (58) | (92) | (46) | +404.7% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | (1,491.34) | (469.17) | 79.03 | (862.00) | (106.77) | (345.44) | (245.66) | (345.4) pt | ||||||
| Net income | — | 0 | 0 | 6 | (208) | (100) | 14 | (196) | (58) | (92) | (46) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 7.75 | 3.18 | 1.28 | 1.28 | 2.48 | 1.04 | 0.64 | n/m | |||||
| Earnings | — | — | 0.00 | 6.47 | (113.06) | (14.90) | 1.00 | (11.02) | (2.64) | (3.59) | (1.69) | +203.9% | ||||||
| Cash flow | — | — | 0.00 | (1.21) | (34.31) | (16.42) | (9.85) | (2.17) | (0.29) | (0.52) | (0.31) | +157.0% | ||||||
| Capex | — | — | 0.00 | 0.00 | (15.11) | (0.92) | (0.37) | (0.06) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | 0.00 | (1.21) | (49.42) | (17.34) | (10.23) | (2.23) | (0.30) | (0.52) | (0.31) | +157.0% | ||||||
| Book value | — | — | 0.03 | 5.50 | 10.16 | 14.83 | 14.22 | 2.30 | 0.40 | (1.49) | (1.22) | n/m | ||||||
| Shares, m | — | — | 1 | 1 | 2 | 7 | 14 | 18 | 22 | 26 | 28 | +65.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 11.45 | 0.00 | 0.00 | 0.00 | 0.00 | 1.9 | |||||
| P/S | — | — | — | — | 0.00 | 16.09 | 8.80 | 2.19 | 0.84 | 1.07 | 1.19 | 4.8 | ||||||
| P/B | — | — | — | — | 0.00 | 3.45 | 0.79 | 1.22 | 5.15 | 0.00 | 0.00 | 1.8 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 15.81 | 11.67 | 5.05 | 1.61 | 2.64 | 3.45 | 6.1 | ||||||
| EV/FCF | — | — | — | — | (2.78) | (2.90) | (1.47) | (2.89) | (13.27) | (5.22) | (7.09) | (4.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | (1) | (63) | (110) | (138) | (39) | (6) | (13) | (9) | +328.5% | |||||
| Capex | — | — | — | — | (28) | (6) | (5) | (1) | 0 | — | 0 | (72.4%) | ||||||
| Free cash flow | — | — | 0 | (1) | (91) | (116) | (143) | (40) | (7) | (13) | (9) | +328.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 1 | 45 | 33 | (29) | (48) | (33) | (68) | (53) | +145.9% | |||||
| Net debt | — | — | 0 | (1) | (24) | (6) | 52 | 39 | 42 | 42 | 42 | +129.2% | ||||||
| Shareholders’ equity | — | — | 0 | 5 | 19 | 99 | 199 | 41 | 9 | (38) | (36) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (1.26) | 4.03 | (57.63) | (23.69) | 3.48 | (72.04) | (41.86) | (76.50) | (42.72) | (75.2) pt | |||||
| ROIC | — | — | (0.46) | (25.77) | 0.00 | (73.05) | (6.39) | (150.27) | (47.58) | (1,070.92) | (462.77) | (1,070.5) pt | ||||||
| ROE | — | — | 0.00 | 234.03 | 79.12 | 46.35 | 9.51 | (163.67) | (232.51) | 628.23 | 151.53 | +628.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 225 | 225 | 120 | 123 | 115 | — | (15.4%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.09 | 0.08 | 0.19 | 0.44 | 0.23 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026
Celularity, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RNAZ TransCode Therapeutics Inc. | $25.6M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AARD Aardvark Therapeutics, Inc. | $24.3M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | Compare |
| CVM Cel-Sci Corporation | $24.1M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $23.5M | — (loss-making) | — (loss-making) | −5.30% (below 0%: shrinking) | n/m | −10.91% (below 0%: shrinking) | 56.79% | (78.00%) | |
| NXTC NextCure, Inc. | $23.4M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.0M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IGC IGC Pharma, Inc. | $22.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −45.33% (below 0%: shrinking) | 18.60% | (588.72%) | Compare |
| CRVO CervoMed Inc. | $21.9M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FLNA Cassava Sciences, Inc. | $21.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $23.2M | — | — | +664.02% | — | −17.49% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 7 November 2025
Ownership
Directors and executive officers, together
17.30%
Tan Sri Lim Kok Thay
39.20%
Dragasac Limited
22.40%
Robert J. Hariri, M.D., Ph.D.
13.40%
Resorts World Inc Pte Ltd
12.70%
Starr International Investments Ltd.
6.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement